Which technology was named as a way the Keylong centre will try to improve healthcare in remote areas?

The correct answer is Himachal Pradesh, where the centre is coming up at Keylong, the administrative centre of the Lahaul and Spiti area. The Union Health Minister performed the Bhumi Pujan and laid the foundation stone there, and a former Chief Minister of the state as well as the Member of Parliament from Mandi spoke at the ceremony. Options A, C and D are all Himalayan states whose people the centre's findings are expected to help, along with Ladakh and Jammu and Kashmir, which is exactly why they make effective distractors: the benefit is spread across the Himalayan belt even though the institution itself sits in one state. The centre builds on a field station that the Indian Council of Medical Research set up at Keylong nearly a decade ago, and it will now become a permanent, year-round institution with modern laboratories and specialist staff.

The correct answer is the Indian Council of Medical Research and the Armed Forces Medical Services, a pairing meant to join scientific research capacity to the practical experience of personnel who work at extreme altitudes. AIIMS Bilaspur is the third institution involved, and its role is to study the health impact of high-altitude conditions on patients who come to the region. Option A is wrong because the Indian Air Force sent senior officers to the ceremony and the DGFMS is an Air Marshal, but the research partnership is with the medical services rather than with DRDO. Options C and D name councils and organisations that work on industrial research, agriculture and border roads, none of which is part of this arrangement. The research will support acclimatisation protocols, early detection and treatment for soldiers as well as care for local communities.

The correct answer is foreign patients arriving on Medical and Ayush Visas. The Union Health Secretary's letter asks states and union territories to encourage the prominent display, wherever applicable, of the package rates offered to international patients travelling to India on these visas. The reasoning is that clear pricing lets such patients choose with full information, reduces grievances about pricing and billing, and strengthens India's position as a trusted destination for medical and Ayush care. Options A, C and D describe categories of patients who would of course benefit from transparent rates in general, but none of them is the group singled out in the letter for package rate display. The broader direction remains that every clinical establishment should show its rates where patients can easily see them.

The correct answer is the local language as well as English. The Rules require a clinical establishment to put up its rates at a conspicuous place in both, so that patients and the people accompanying them can read the charges without having to ask. Option A would leave out those who do not read English, which defeats the purpose of the provision. Option B is wrong because the requirement is for the local language, which need not be Hindi and will differ from state to state. Option D is not the test laid down: the Rules do not leave the choice of a single language to the establishment. The purpose behind the bilingual requirement is to let patients estimate the likely cost of treatment, plan their spending and avoid disputes over billing.

The correct answer is the Clinical Establishments (Registration and Regulation) Act, 2010, read with the Clinical Establishments (Central Government) Rules, 2012. Together they form the regulatory framework for clinical establishments, and the Rules require that the rate charged for each type of service and each facility be displayed at a conspicuous place, in the local language as well as in English. Option B governs medical education and the registration of practitioners, not the display of hospital charges. Option C deals with consumer rights and redressal in general and is not the instrument the Health Secretary's letter relies on. Option D regulates the manufacture, sale and quality of drugs and cosmetics. Only the 2010 Act, with its Rules, carries the display obligation that the Centre has asked states to enforce.